Atwood & Palmer’s Globus Medical GMED Stock Holding History

Atwood & Palmer’s Portfolio GMED Stock Details GMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5	Closed	-$249	–	416
2023 Q3	$249	Buy	+5	New	+$280	﹤0.01%	393

Other funds holding GMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Atwood & Palmer's GMED Position: Q4 2023 in Review

Atwood & Palmer sold out of Globus Medical (GMED) in Q4 2023, closing a stake of 5 shares — an estimated $249 sold.

Atwood & Palmer first reported a position in GMED in Q3 2023 and held it in 1 quarter. The position peaked at $249 in Q3 2023. 408 funds tracked by Wall St. Rank hold GMED as of Q4 2023.

Atwood & Palmer reported no remaining Globus Medical position as of Q4 2023 after selling out during the quarter.
Atwood & Palmer sold 5 Globus Medical shares in Q4 2023, an estimated $249.
Atwood & Palmer first reported a position in Globus Medical in Q3 2023 and held it in 1 quarter.
Atwood & Palmer's Globus Medical position peaked at $249 in Q3 2023.
408 funds tracked by Wall St. Rank held Globus Medical as of Q4 2023.

Based on Atwood & Palmer's 13F filing for Q4 2023, filed 12 Jan 2024.